First Allied Advisory Services’s Avadel Pharmaceuticals AVDL Stock Holding History

First Allied Advisory Services’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-10,000	Closed	-$171K	–	1078
2014 Q4	$171K	Buy	+10,000	New	+$143K	0.01%	953

Other funds holding AVDL

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

First Allied Advisory Services's AVDL Position: Q1 2015 in Review

First Allied Advisory Services sold out of Avadel Pharmaceuticals (AVDL) in Q1 2015, closing a stake of 10,000 shares — an estimated $171K sold.

First Allied Advisory Services first reported a position in AVDL in Q4 2014 and held it in 1 quarter. The position peaked at $171K in Q4 2014. 84 funds tracked by Wall St. Rank hold AVDL as of Q1 2015.

First Allied Advisory Services reported no remaining Avadel Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
First Allied Advisory Services sold 10,000 Avadel Pharmaceuticals shares in Q1 2015, an estimated $171K.
First Allied Advisory Services first reported a position in Avadel Pharmaceuticals in Q4 2014 and held it in 1 quarter.
First Allied Advisory Services's Avadel Pharmaceuticals position peaked at $171K in Q4 2014.
84 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2015.

Based on First Allied Advisory Services's 13F filing for Q1 2015, filed 15 May 2015.